• Hamlet Biopharma signed an agreement with the University of Iowa to expand a US clinical study of Alpha1H for high-risk NMIBC.
• The expansion adds bladder carcinoma in situ, targeting patients with therapy-resistant disease who often face bladder removal.
• No new trial results were presented; the study is planned under the existing US IND via an FDA protocol amendment.
• The move broadens Alpha1H’s clinical development into a tougher segment where standard BCG therapy frequently fails to deliver durable responses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.